Lilly Surges with Drug Breakthroughs | Business and Finance News

Eli Lilly is crushing it in Q2 2026 with a 48% revenue surge, driven by blockbuster drugs in oncology, immunology, and neuroscience—some growing over 120%. Foundayo, their diabetes-obesity drug, is gaining momentum globally, with U.S. approval pending and strong traction in the UAE. Regulatory wins for Ebglyss and Jaypirca, plus promising late-stage data for retatrutide, signal a powerful pipeline. Strategic acquisitions in infectious diseases and mental health, plus new manufacturing facilities, are expanding their reach. Patient access is improving thanks to Medicare’s GLP-1 Bridge program. Financials are stellar: Mounjaro and Zepbound are driving growth worldwide, margins are up, R&D investment is rising, and EPS has jumped significantly. Eli Lilly is clearly on a winning streak—innovation, scale, and financial strength all in sync for sustained success. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/44aae1884cd2d653